From first‐trimester screening to risk stratification of evolving pre‐eclampsia in  second and third trimesters of pregnancy: comprehensive approach

Poon, Liona C.; Galindo, Alberto; Surbek, Daniel; Chantraine, Frédéric; Stepan, Holger; Hyett, Jon; Tan, Kok Hian; Verlohren, Stefan

doi:10.1002/uog.21869

Cited by 27 publications

(24 citation statements)

References 64 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…45e47 Following the advances in first-trimester screening, where many studies have shown the excellent performance of the predictive algorithms, the sFlt-1etoePlGF ratio is an important means for follow-up of patients at high risk as identified by early screening. 48 The Combined Multimarker Screening and Randomized Patient Treatment with Aspirin for Evidence-Based Preeclampsia Prevention (ASPRE) study has clearly shown the necessity of early screening and prophylaxis. The early initiation of a 150 mg per day intake of aspirin with therapy adherence of !90%, starting from 11 to 14 weeks' gestation to 36 weeks' gestation, decreased the presence of early-onset PE with an odds ratio ajog.org Expert Review Verlohren.…”

Section: Multimarker Modeling Including Angiogenic Factors In Outcome Predictionmentioning

confidence: 99%

“…49e53 However, a comprehensive approach of following up these patients during pregnancy includes repeated screening and surveillance with the help of angiogenic and antiangiogenic factors as women stay at high risk despite receiving aspirin. 48 Predicting Preeclampsia-Related Adverse Outcomes with Angiogenic and Antiangiogenic Factors Most clinical studies that evaluated the diagnostic and predictive use of biomarkers chose the endpoint "PE," as defined by the old ISSHP or ACOG definition. In 2012, Rana et al 41 was the first to evaluate the accuracy of the sFlt-1etoePlGF ratio when focusing on PErelated complications: in a prospective clinical study on 616 women with suspected PE, they evaluated the use of the sFlt-1etoePlGF ratio to predict adverse outcomes, defined as the presence of hypertension plus severe outcome features, such as delivery before 34 weeks' gestation, lung edema, and placental abruption.…”

Section: Expert Reviewmentioning

confidence: 99%

See 1 more Smart Citation

The diagnostic value of angiogenic and antiangiogenic factors in differential diagnosis of preeclampsia

Verlohren

Dröge

2022

American Journal of Obstetrics and Gynecology

Self Cite

View full text Add to dashboard Cite

Section: Multimarker Modeling Including Angiogenic Factors In Outcome Predictionmentioning

confidence: 99%

Section: Expert Reviewmentioning

confidence: 99%

The diagnostic value of angiogenic and antiangiogenic factors in differential diagnosis of preeclampsia

Verlohren

Dröge

2022

American Journal of Obstetrics and Gynecology

Self Cite

View full text Add to dashboard Cite

“…5 School of Life Course Science, King's College London, London, UK. 6 Leeds Institute of Health Sciences, University of Leeds, Leeds, UK.…”

Section: Abbreviationsmentioning

confidence: 99%

“…Effective treatment for preeclampsia is delivery, regardless of gestational age, which will not always prevent or ameliorate postpartum preeclampsia [ 4 , 5 ]. A history of preeclampsia raises risk of preeclampsia in subsequent pregnancies and risk of cardiovascular disease in subsequent years above that of women with normotensive pregnancy history [ 6 ]. Prophylactic low-dose aspirin (LDA) lowers the risk of developing preterm preeclampsia [ 7 ].…”

Section: Introductionmentioning

confidence: 99%

Women’s attitudes, beliefs and values about tests, and management for hypertensive disorders of pregnancy

Ahmed

Brewer

Tsigas

et al. 2021

BMC Pregnancy Childbirth

View full text Add to dashboard Cite

Background Advances in research suggest the possibility of improving routine clinical care for preeclampsia using screening (predictive) and diagnostic tests. The views of women should be incorporated into the way in which such tests are used. Therefore, we explored the views of women with experience of preeclampsia and other hypertensive disorders in pregnancy (HDPs) about predictive and diagnostic tests, treatment risks, and expectant management. Method Eight hundred and seven women with experience of preeclampsia or other HDPs completed an online questionnaire. These women were participants in the Preeclampsia Registry (USA). The questionnaire contained 22 items to elicit women’s views about predictive tests (n = 8); diagnostic tests (n = 5); treatment risks (n = 7), and expectant management (n = 2). An optional text box allowed participants to add qualitative open-ended comments. Levels of agreement with the statements were reported descriptively for the sample as a whole, and a preliminary investigation of the role of lived experience in shaping women’s views was conducted by comparing subgroups within the sample based on time of HDP delivery (preterm/term). The qualitative data provided in the optional text box was analysed using inductive thematic analysis to examine participants’ responses. Results Women generally favored predictive and diagnostic testing, although not because they would opt for termination of pregnancy. Participants generally disagreed that taking daily low-dose aspirin (LDA) would make them nervous, with disagreement significantly higher in the preterm delivery subgroup. A high proportion of participants, especially in the preterm delivery subgroup, would take LDA throughout pregnancy. The majority of participants would be more worried about the possibility of preeclampsia than about the risks of treatments to their health (60%), and that proportion was significantly higher in the preterm delivery subgroup. There were no differences between subgroups in the views expressed about expectant management, although opinion was divided in both groups. Overall, most participants opted to put the baby’s interests first. Conclusion Women with experience of hypertensive disorders were enthusiastic about improved predictive and diagnostic tests. However, varied views about treatment options and expectant management suggest the need for a shared decision-making tool to enable healthcare professionals to support pregnant women’s decision-making to maximize the utility of these tests and interventions.

show abstract

“…32 The prediction model adopted by the Fetal Medical Foundation has been validated in Europe 33 and more recently evaluated in other parts of the world. 34e37 Poon et al 38 and De Kat et al 39 provide a detailed review of the existing predictive models.…”

mentioning

confidence: 99%

Early prediction of preeclampsia via machine learning

Marić

Tsur

Aghaeepour

et al. 2020

American Journal of Obstetrics & Gynecology MFM

View full text Add to dashboard Cite

From first‐trimester screening to risk stratification of evolving pre‐eclampsia in second and third trimesters of pregnancy: comprehensive approach

Cited by 27 publications

References 64 publications

The diagnostic value of angiogenic and antiangiogenic factors in differential diagnosis of preeclampsia

The diagnostic value of angiogenic and antiangiogenic factors in differential diagnosis of preeclampsia

Women’s attitudes, beliefs and values about tests, and management for hypertensive disorders of pregnancy

Early prediction of preeclampsia via machine learning

Contact Info

Product

Resources

About